, Volume 60, Issue 12, pp 2538–2539 | Cite as

Cancer risk in the EMPA-REG OUTCOME trial. Reply to Shaikh AMY [letter] and Kohler S, Lee J, George JT et al [letter]



Bladder cancer Empagliflozin SGLT2 inhibitors 



Food and Drug Administration


Sodium–glucose cotransporter 2



The authors would like to thank Q. Dai from the Department of Medicine, School of Medicine, Vanderbilt University, USA, and W. Shi and S. Zhai from the Department of Pharmacy, Peking University Third Hospital, China, who contributed to the previous study.


YS was supported by the Indiana University Health–Indiana University School of Medicine Strategic Research Initiative.

Duality of interest

The authors declare that there is no duality of interest associated with this manuscript.

Contribution statement

All authors contributed to data interpretation, drafted the report, and critically reviewed the report. All authors approved the final version of the manuscript.


  1. 1.
    Shaikh AMY (2017) SGLT2 inhibitors and cancer: why further evidence is required. Diabetologia
  2. 2.
    Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128CrossRefPubMedGoogle Scholar
  3. 3.
    Tang H, Dai Q, Shi W, Zhai S, Song Y, Han J (2017) SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetologia
  4. 4.
    US Food and Drug Administration (2007) Food and Drug Administration Amendments Act of 2007. Public Law 110-85. Available from Accessed 12 August 2017
  5. 5.
    Kohler S, Lee J, George JT, Inzucchi SE, Zinman B (2017) Bladder cancer in the EMPA-REG OUTCOME trial. Diabetologia

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  1. 1.Department of Epidemiology, Richard M. Fairbanks School of Public HealthIndiana UniversityIndianapolisUSA
  2. 2.Melvin and Bren Simon Cancer CenterIndiana UniversityIndianapolisUSA

Personalised recommendations